A Phase 1 interventional study of cobimetinib in Healthy Volunteer, sponsored by Genentech, Inc.. Completed at 3 sites in United States. Open to participants aged 18 Years to 74 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-02-19.
Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 1 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is an open-label, multi-center, single-dose, parallel group study to determine the pharmacokinetics, safety, and tolerability of cobimetinib administered at 10 mg to fasted male and female adult subjects with varying degrees of hepatic function. The study will be conducted based on the Child-Pugh classification of hepatic impairment. The anticipated duration of the study is 7.5 weeks. The target sample sizes are: 18 volunteers with varying degrees of hepatic function and up to 12 healthy control volunteers.
Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
First submitted after Genentech, Inc. became part of Hoffmann-La Roche.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: cobimetinib
Drug: cobimetinib
Drug: cobimetinib
Drug: cobimetinib
single oral 10-mg dose of cobimetinib
Maximum Observed Plasma Concentration (Cmax)
Time frame: Pre-dose (0 hours [hrs]), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, 216, 264, 336, 456, and 576 hrs post-dose
Time to Reach Maximum Observed Plasma Concentration (Tmax)
Time frame: Pre-dose (0 hrs), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, 216, 264, 336, 456, and 576 hrs post-dose
Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)]
AUC (0-t) was defined as area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-t).
Time frame: Pre-dose (0 hrs), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, 216, 264, 336, 456, and 576 hrs post-dose
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]
AUC (0 - ∞) was defined as AUC from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t- ∞).
Time frame: Pre-dose (0 hrs), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, 216, 264, 336, 456, and 576 hrs post-dose
Extrapolated Area Under the Curve (AUC Percent [%] Extrapolated)
AUC% extrapolated was defined as the percentage of AUC \[0-∞\] obtained by forward extrapolation. It is calculated as \[AUC (0-∞) minus AUC(0-t\]\*100/ AUC (0-∞), where AUC \[0-∞\] = Area under the plasma concentration versus time curve from time zero (pre-dose) to extrapolated infinite time (0-∞) and AUC(0-t) is area under the plasma concentration time-curve from zero (pre-dose) to the last measured concentration.
Time frame: Pre-dose (0 hrs), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, 216, 264, 336, 456, and 576 hrs post-dose
Apparent Terminal Elimination Rate Constant (λZ)
λZ was defined as the magnitude of the slope of the linear regression of the log concentration versus time profile during the terminal phase.
Time frame: Pre-dose (0 hrs), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, 216, 264, 336, 456, and 576 hrs post-dose
Plasma Decay Half-Life (t1/2)
Plasma decay half-life is the time measured for the plasma concentration of cobimetinib to decrease by one half.
Time frame: Pre-dose (0 hrs), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, 216, 264, 336, 456, and 576 hrs post-dose
Apparent Oral Clearance (CL/F)
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
Time frame: Pre-dose (0 hrs), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, 216, 264, 336, 456, and 576 hrs post-dose
Apparent Volume of Distribution (Vz/F)
Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Vz/F after the oral dose is influenced by the fraction absorbed.
Time frame: Pre-dose (0 hrs), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, 216, 264, 336, 456, and 576 hrs post-dose
| Milestone | Cohort 1: Normal Hepatic Function | Cohort 2: Mild Hepatic Impairment | Cohort 3: Moderate Hepatic Impairment | Cohort 4: Severe Hepatic Impairment |
|---|---|---|---|---|
| Started | 10 | 6 | 6 | 6 |
| Completed | 10 | 6 | 6 | 6 |
| Not completed | 0 | 0 | 0 | 0 |
| nanograms per milliliter (ng/mL) | Cohort 1: Normal Hepatic Function | Cohort 2: Mild Hepatic Impairment | Cohort 3: Moderate Hepatic Impairment | Cohort 4: Severe Hepatic Impairment |
|---|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) | 10.7 ± 7.41 | 9.00 ± 4.09 | 8.03 ± 2.49 | 3.97 ± 1.77 |
| hrs | Cohort 1: Normal Hepatic Function | Cohort 2: Mild Hepatic Impairment | Cohort 3: Moderate Hepatic Impairment | Cohort 4: Severe Hepatic Impairment |
|---|---|---|---|---|
| Time to Reach Maximum Observed Plasma Concentration (Tmax) | 2 (1 to 6) | 6 (2 to 6) | 4 (2 to 6) | 2 (1 to 4) |
AUC (0-t) was defined as area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-t).
| ng*hr/mL | Cohort 1: Normal Hepatic Function | Cohort 2: Mild Hepatic Impairment | Cohort 3: Moderate Hepatic Impairment | Cohort 4: Severe Hepatic Impairment |
|---|---|---|---|---|
| Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] | 604 ± 606 | 498 ± 200 | 539 ± 296 | 268 ± 181 |
AUC (0 - ∞) was defined as AUC from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t- ∞).
| ng*hr/mL | Cohort 1: Normal Hepatic Function | Cohort 2: Mild Hepatic Impairment | Cohort 3: Moderate Hepatic Impairment | Cohort 4: Severe Hepatic Impairment |
|---|---|---|---|---|
| Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] | 637 ± 606 | 530 ± 206 | 579 ± 301 | 370 ± 163 |
AUC% extrapolated was defined as the percentage of AUC \[0-∞\] obtained by forward extrapolation. It is calculated as \[AUC (0-∞) minus AUC(0-t\]\*100/ AUC (0-∞), where AUC \[0-∞\] = Area under the plasma concentration versus time curve from time zero (pre-dose) to extrapolated infinite time (0-∞) and AUC(0-t) is area under the plasma concentration time-curve from zero (pre-dose) to the last measured concentration.
| % extrapolated | Cohort 1: Normal Hepatic Function | Cohort 2: Mild Hepatic Impairment | Cohort 3: Moderate Hepatic Impairment | Cohort 4: Severe Hepatic Impairment |
|---|---|---|---|---|
| Extrapolated Area Under the Curve (AUC Percent [%] Extrapolated) | 7.37 ± 4.37 | 6.69 ± 2.63 | 8.17 ± 4.36 | 15.90 ± 4.79 |
λZ was defined as the magnitude of the slope of the linear regression of the log concentration versus time profile during the terminal phase.
| 1 per hr (1/hr) | Cohort 1: Normal Hepatic Function | Cohort 2: Mild Hepatic Impairment | Cohort 3: Moderate Hepatic Impairment | Cohort 4: Severe Hepatic Impairment |
|---|---|---|---|---|
| Apparent Terminal Elimination Rate Constant (λZ) | 0.00942 ± 0.00259 | 0.00852 ± 0.00315 | 0.00702 ± 0.00181 | 0.00509 ± 0.00114 |
Plasma decay half-life is the time measured for the plasma concentration of cobimetinib to decrease by one half.
| hr | Cohort 1: Normal Hepatic Function | Cohort 2: Mild Hepatic Impairment | Cohort 3: Moderate Hepatic Impairment | Cohort 4: Severe Hepatic Impairment |
|---|---|---|---|---|
| Plasma Decay Half-Life (t1/2) | 79.1 ± 22.7 | 95.2 ± 48.2 | 104.0 ± 24.4 | 143.0 ± 40.4 |
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
| Liter per hr (L/hr) | Cohort 1: Normal Hepatic Function | Cohort 2: Mild Hepatic Impairment | Cohort 3: Moderate Hepatic Impairment | Cohort 4: Severe Hepatic Impairment |
|---|---|---|---|---|
| Apparent Oral Clearance (CL/F) | 23.4 ± 11.6 | 22.9 ± 13.2 | 21.9 ± 11.7 | 31.7 ± 14.5 |
Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Vz/F after the oral dose is influenced by the fraction absorbed.
| Liter | Cohort 1: Normal Hepatic Function | Cohort 2: Mild Hepatic Impairment | Cohort 3: Moderate Hepatic Impairment | Cohort 4: Severe Hepatic Impairment |
|---|---|---|---|---|
| Apparent Volume of Distribution (Vz/F) | 2580 ± 1300 | 2880 ± 1370 | 3230 ± 1650 | 6280 ± 2480 |
Collected over Up to 30 days after the last dose of study drug (up to approximately 2 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: Normal Hepatic Function | — | 0/10 (0%) | 3/10 (30%) |
| Cohort 2: Mild Hepatic Impairment | — | 0/6 (0%) | 3/6 (50%) |
| Cohort 3: Moderate Hepatic Impairment | — | 0/6 (0%) | 2/6 (33.3%) |
| Cohort 4: Severe Hepatic Impairment | — | 0/6 (0%) | 1/6 (16.7%) |
| Event | Cohort 1: Normal Hepatic Function | Cohort 2: Mild Hepatic Impairment | Cohort 3: Moderate Hepatic Impairment | Cohort 4: Severe Hepatic Impairment |
|---|---|---|---|---|
| DyspepsiaGastrointestinal disorders | 0/10 | 1/6 | 0/6 | 0/6 |
| Abdominal painGastrointestinal disorders | 0/10 | 0/6 | 1/6 | 0/6 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 0/10 | 0/6 | 1/6 | 0/6 |
| Vessel puncture site haematomaGeneral disorders | 0/10 | 1/6 | 0/6 | 0/6 |
| Muscle strainInjury, poisoning and procedural complications | 0/10 | 0/6 | 1/6 | 0/6 |
| DizzinessNervous system disorders | 0/10 | 1/6 | 0/6 | 0/6 |
| HeadacheNervous system disorders | 1/10 | 0/6 | 0/6 | 1/6 |
| HaematocheziaGastrointestinal disorders | 1/10 | 0/6 | 0/6 | 0/6 |
| GoutMetabolism and nutrition disorders | 1/10 | 0/6 | 0/6 | 0/6 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 1/10 | 0/6 | 0/6 | 0/6 |
Safety population included all participants who received at least one dose of cobimetinib and had at least one post-dose safety assessment.
| Age, Continuous(Years) | Cohort 1: Normal Hepatic Function | Cohort 2: Mild Hepatic Impairment | Cohort 3: Moderate Hepatic Impairment | Cohort 4: Severe Hepatic Impairment | Total |
|---|---|---|---|---|---|
| Mean | 56 ± 6.8 | 59 ± 2.8 | 61 ± 2.9 | 53 ± 5.3 | 57 ± 5.6 |
| Sex: Female, Male(Participants) | Cohort 1: Normal Hepatic Function | Cohort 2: Mild Hepatic Impairment | Cohort 3: Moderate Hepatic Impairment | Cohort 4: Severe Hepatic Impairment | Total |
|---|---|---|---|---|---|
| Female | 3 | 3 | 1 | 2 | 9 |
| Male | 7 | 3 | 5 | 4 | 19 |
The record gives a start of Aug 2014, a primary completion of Jan 2015 and a completion of Jan 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2016, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cobimetinib